Academia Urges More Transparency on Labels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Academia Urges More Transparency on Labels


ePT--the Electronic Newsletter of Pharmaceutical Technology

Researchers from the Stanford University School of Medicine in California are urging the US Food and Drug Administration to demand that drug manufacturers state how new medications compare with similar treatments on product labels. "In many instances, these statements would indicate that there is no evidence that a new drug is more effective than older ones," according to a Stanford news release.

Stafford and his fellow researchers published an essay on the subject in the New England Journal of Medicine. They recommend that FDA require new drugs to carry a label that says, for example: "Although this drug has been shown to lower blood pressure more effectively than placebo, it has not been shown to be more effective than other members of the same drug class." The researchers believe that "developing more informative labels is consistent with the agency's recently invigorated function as a public health agency." (see back story, A Fresh Perspective at FDA.)

The researchers believe that making such information available may influence the decisions made by patients and healthcare insurers. New drugs are often more expensive than existing therapies and may be no more effective. "The public's appetite for the latest drugs might be curbed if patients understood that new treatments aren't necessarily more effective than existing ones," explained the news release.

"Drug and device manufacturers benefit from an unacknowledged information gap that develops as more and more products are tested against placebo, but not each other," said Randell Stafford, associate professor of medicine at the Stanford Prevention Research Center, in the release.

Stephanie Sutton is an assistant editor with PharmTech Europe.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here